Evidence map›Paper›PMID 30826218›Full record

SynthesisEuropean urology2019

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.

Sarah Burdett, Liselotte M Boevé, Fiona C Ingleby, David J Fisher, Larysa H Rydzewska, Claire L Vale, George van Andel, Noel W Clarke, Maarten C Hulshof, Nicholas D James and 8 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Review
  16. Individualized radiotherapy of bone metastases from prostate cancer: time trends and 5-year survival results.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  17. Review
  18. Review
  19. Head-to-head comparison ofEJNMMI research · 2026
    Article
  20. Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Sarah BurdettMeta-analysis Group, MRC Clinical Trials Unit at UCL, London, UK. Electronic address: sarah.burdett@ucl.ac.uk.
Liselotte M BoevéDepartment of Urology, OLVG, Amsterdam, The Netherlands; Department of Urology, Amsterdam UMC (VU), Amsterdam, The Netherlands.
Fiona C InglebyMRC Clinical Trials Unit at UCL, London, UK.
David J FisherMeta-analysis Group, MRC Clinical Trials Unit at UCL, London, UK.
Larysa H RydzewskaMeta-analysis Group, MRC Clinical Trials Unit at UCL, London, UK.
Claire L ValeMeta-analysis Group, MRC Clinical Trials Unit at UCL, London, UK.
George van AndelDepartment of Urology, Amsterdam UMC (VU), Amsterdam, The Netherlands.
Noel W ClarkeThe Christie and Salford Royal Hospitals, Manchester, UK.
Maarten C HulshofDepartment of Radiotherapy, Amsterdam UMC (AMC), Amsterdam, The Netherlands.
Nicholas D JamesInstitute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
Christopher C ParkerRoyal Marsden Hospital, Sutton, Institute of Cancer Research, Sutton, UK.
Mahesh K ParmarMRC Clinical Trials Unit at UCL, London, UK.
Christopher J SweeneyDana-Faber Cancer Institute, Boston, MA, USA.
Matthew R SydesMRC Clinical Trials Unit at UCL, London, UK.
Bertrand TombalDepartment of Urology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
Paul C VerhagenDepartment of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Jayne F TierneyMeta-analysis Group, MRC Clinical Trials Unit at UCL, London, UK.
STOPCAP M1 Radiotherapy Collaborators

Funding

Cancer Research UK 3804Medical Research Council MC_UU_12023/25
6 · The paper itself

Abstract

backgroundMany trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC).

objectiveTo systematically review trials of prostate radiotherapy. DESIGN, SETTING, AND

participantsUsing a prospective framework (framework for adaptive meta-analysis [FAME]), we prespecified methods before any trial results were known. We searched extensively for eligible trials and asked investigators when results would be available. We could then anticipate that a definitive meta-analysis of the effects of prostate radiotherapy was possible. We obtained prepublication, unpublished, and harmonised results from investigators.

interventionWe included trials that randomised men to prostate radiotherapy and androgen deprivation therapy (ADT) or ADT only. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Hazard ratios (HRs) for the effects of prostate radiotherapy on survival, progression-free survival (PFS), failure-free survival (FFS), biochemical progression, and subgroup interactions were combined using fixed-effect meta-analysis. RESULTS AND LIMITATIONS: We identified one ongoing (PEACE-1) and two completed (HORRAD and STAMPEDE) eligible trials. Pooled results of the latter (2126 men; 90% of those eligible) showed no overall improvement in survival (HR=0.92, 95% confidence interval [CI] 0.81-1.04, p=0.195) or PFS (HR=0.94, 95% CI 0.84-1.05, p=0.238) with prostate radiotherapy. There was an overall improvement in biochemical progression (HR=0.74, 95% CI 0.67-0.82, p=0.94×10

conclusionsProstate radiotherapy should be considered for men with mHSPC with a low metastatic burden. PATIENT SUMMARY: Prostate cancer that has spread to other parts of the body (metastases) is usually treated with hormone therapy. In men with fewer than five bone metastases, addition of prostate radiotherapy helped them live longer and should be considered.

Indexed as

Bone NeoplasmsDisease-Free SurvivalGonadotropin-Releasing HormoneHumansMaleOrchiectomyProgression-Free SurvivalProstate-Specific AntigenProstatic NeoplasmsRandomized Controlled Trials as TopicSurvival RateTumor BurdenGonadotropin-Releasing HormoneProstate-Specific AntigenAndrogen deprivation therapyMeta-analysisMetastasesProstate cancerRadiotherapyStandard of careSystematic review

Identifiers

PMID30826218
PMCPMC6575150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.